{"ticker": {"uuid": "88a8091e-13f7-4ecd-95ab-57f2eff812af", "symbol": "PLUR", "name": "Pluri Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pluri chairman raises stake above 30%; shares up", "summary": "Pluri's chairman, Zami Aberman, has increased his stake in the company to over 30%, reflecting strong confidence in the biotech firm without triggering a mandatory tender offer. This significant acquisition led to an almost 10% rise in Pluri's shares. The company is actively deve", "url": "https://www.msn.com/en-us/money/companies/pluri-chairman-raises-stake-above-30-shares-up/ar-AA27TQNh", "source_name": "MSN", "published_at": "2026-07-15T00:11:21", "published_display": "15 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Chairman Builds 30%-Plus Position With $17M Investment", "summary": "Pluri Inc. announced that Chairman Alejandro Weinstein has invested over $17 million in the company during the past year, increasing his ownership to more than 30%. This significant investment includes a $1.25 million advance made in June 2026, coinciding with Pluri's strategic s", "url": "https://www.stocktitan.net/news/PLUR/pluri-chairman-alejandro-weinstein-s-cumulative-investment-exceeds-nxv79id2x61f.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:10:33", "published_display": "14 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 88, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Chairman Alejandro Weinstein\u2019s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%", "summary": "Pluri Inc. Chairman Alejandro Weinstein has increased his investment in the company to over $17 million, resulting in an ownership stake exceeding 30%. This significant commitment comes as Pluri transitions its focus towards commercialization, particularly in the longevity sector", "url": "https://finance.yahoo.com/healthcare/articles/pluri-chairman-alejandro-weinstein-cumulative-110000776.html", "source_name": "Market source", "published_at": "2026-07-14T11:10:33", "published_display": "14 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Pluri Inc. (PLUR) received a notice from Nasdaq on July 7, 2026, indicating non-compliance with Listing Rule 5550(b)(2) due to failing to maintain a market value of listed securities of at least $35 million or meet alternative equity or net income standards. The company has 180 d", "url": "https://www.tradingview.com/news/tradingview:626ab314ea8be:0-pluri-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-07-13T20:13:27", "published_display": "13 Jul 2026 20:13", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pluri (PLUR) director Doron Shorrer files Form 3 listing share holdings", "summary": "Pluri Inc. director Doron Shorrer has filed a Form 3, disclosing his beneficial ownership of the company's common stock. The filing indicates direct ownership of 6,659 shares and indirect ownership of 6,969 shares through Shorrer International Ltd. This initial statement is requi", "url": "https://www.stocktitan.net/sec-filings/PLUR/form-3-pluri-inc-initial-statement-of-beneficial-ownership-085f3cdc66b9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:10:28", "published_display": "07 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUR - Pluri Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Pluri Inc. (PLUR). It includes key metrics such as market capitalization, income, sales, earnings per share, insider ownership, and various performance indicators. The data offers an overview of the", "url": "https://finviz.com/stock?t=PLUR&ty=lf&r=ytd&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T05:40:59", "published_display": "04 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Q2 2026 Earnings: Wider-than-Expected Loss Drives Stock Decline - Slow Growth Warning", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQcmVxLXN5UTRQcV8ySUpzX0dlcHdzdDB4MXk3SjdsM3g1NUZXTk5KTkFhbF95X0tSUHFqQ3Nqbm44YWtwYXhqdjNsOTdVSEZBWlJLX0EwR3NiZE10RE1MVGU5Wk4xLTZXMVhpVElOM1FGblp6YzlFRzJzYmNZaDhHR1B3X1hDNTNKTnJpVTZSZnV5VFlPQjQtUGVyV2M5X0doS09BLUp5WnBPN1o2NXNjNV9R?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T09:48:48+00:00", "published_display": "02 Jul 2026 09:48", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Pluri Inc. For: 1 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13D/A by Pluri Inc. for July 1st. It serves as a brief financial markets update, indicating a specific regulatory filing by the company. The text predominantly features navigation, advertisements, and market data rather", "url": "https://uk.investing.com/news/stock-market-news/form-13da-pluri-inc-for-1-july-93CH-4753582", "source_name": "Investing.com UK", "published_at": "2026-07-01T21:06:00", "published_display": "01 Jul 2026 21:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri (NASDAQ: PLUR) director logs RSU grant as 625,000 warrants expire", "summary": "Pluri Inc. director Alexandre Weinstein reported receiving 641 shares of common stock as an RSU grant, increasing his directly held shares to 6,925. Separately, 625,000 common warrants held indirectly through Chutzpah Holdings LP, with an exercise price of $4.25 per share, expire", "url": "https://www.stocktitan.net/sec-filings/PLUR/form-4-pluri-inc-insider-trading-activity-9d8cc2dab38b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:42", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] Pluri Inc. Amended Major Shareholder Report", "summary": "This amended Schedule 13D/A filing for Pluri Inc. details the updated beneficial ownership of major shareholder Alexandre Weinstein and his affiliated entities (Chutzpah Holdings Ltd., Chutzpah Holdings LP, and Plantae Bioscience Ltd.). As of June 30, 2026, the group beneficially", "url": "https://www.stocktitan.net/sec-filings/PLUR/schedule-13d-a-pluri-inc-amended-major-shareholder-report-f0a7bfe95f62.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:42", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pluri Inc. \u2013 NASDAQ:PLUR", "summary": "This article provides financial data for Pluri Inc. (NASDAQ: PLUR), specifically focusing on its price-to-sales forward ratio. The content appears to be a snapshot from a financial platform like TradingView, showing an overview of the company's financials without detailed analysi", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:45", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pluri Inc. \u2013 NASDAQ:PLUR", "summary": "This article provides a financial overview of Pluri Inc. (NASDAQ: PLUR), focusing on its enterprise value to EBITDA forward metric. The content is primarily a data page from TradingView, displaying key financial information for the biotechnology company. It categorizes PLUR withi", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:09:05", "published_display": "27 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pluri Inc. \u2013 NASDAQ:PLUR", "summary": "The article provides a brief overview of Pluri Inc. (NASDAQ: PLUR), focusing on its price to earnings forward metric. It appears to be an excerpt from a financial data platform, showing the company's stock market information and some underlying data sources.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:06", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Actuals & Estimates (NASDAQ:PLUR)", "summary": "This article provides financial actuals and estimates for Pluri Inc. (NASDAQ:PLUR), including its current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings date. It also covers the company's net income, employee count, EBITDA, and te", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:06", "published_display": "26 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Actuals & Estimates (FWB:4DX)", "summary": "This article provides financial actuals and estimates for Pluri Inc. (FWB:4DX), covering income statement, balance sheet, and cash flow data, as well as valuation metrics. It includes frequently asked questions about the company's stock ticker, historical prices, earnings reports", "url": "https://www.tradingview.com/symbols/FWB-4DX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:49", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Actuals & Estimates (TASE:PLUR)", "summary": "This article provides an overview of Pluri Inc. (TASE:PLUR) stock, including its current price, historical performance, market capitalization, and financial estimates. It highlights recent stock price changes, upcoming earnings reports, and key financial metrics like net income a", "url": "https://www.tradingview.com/symbols/TASE-PLUR/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-25T20:40:50", "published_display": "25 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Pluri Inc (PLUR), indicating a current risk score of 2.15, ranking it 235 out of 387 in the Biotechnology & Medical Research industry. Key metrics include a beta value of 0.66, suggesting lower volatility compared to the S&P 500, a 240-", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-25T02:09:49", "published_display": "25 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri (NASDAQ: PLUR) gets $1,250,000 insider advance and appoints new director", "summary": "Pluri Inc. (NASDAQ: PLUR) received a $1,250,000 advance from Chutzpah Holdings LP, an entity beneficially owned by the company's chairman, to be used for working capital and general corporate purposes, with the expectation that it will be credited against securities purchased in ", "url": "https://www.stocktitan.net/sec-filings/PLUR/8-k-pluri-inc-reports-material-event-88087e271e18.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:24", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pluri Inc (PLUR), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock is currently trading between support at $1.81 and resistance at $2.42, with indicators and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/technical", "source_name": "TradingKey", "published_at": "2026-06-22T15:40:10", "published_display": "22 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Pluri Inc (PLUR), highlighting that no earnings forecast score is currently available, but the industry average is 8.15. Analysts project a price target of $12.00 for PLUR, with expected revenue of $655.00K for the next quarter. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:13", "published_display": "18 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Pluri Inc (PLUR), highlighting its current valuation score of 8.50 within the Biotechnology & Medical Research industry, ranking 124 out of 389. The company's P/E ratio is noted at -0.69, which is below its recent high and above its r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:13", "published_display": "18 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Institutional Confidence", "summary": "The article analyzes the institutional confidence score for Pluri Inc (PLUR), which currently stands at 3.00, ranking it 193 out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 14.97% quarter-over-quarter to 12.5", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:39:18", "published_display": "18 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article displays the revenue breakdown for Pluri Inc (PLUR) but notes that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It serves primarily as a placeholder or an indication that this informat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T04:39:43", "published_display": "18 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Pluri Inc (PLUR) has a weak financial status with a score of 5.30, ranking low within the Biotechnology & Medical Research industry. The company reported a significant year-over-year decrease in revenue by 60.89% to $167.00K, alongside a 9.74% decrease in net profit. Its operatio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:43", "published_display": "18 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUR Stock Price and Chart \u2014 NASDAQ:PLUR", "summary": "This article provides a detailed overview of Pluri Inc. (NASDAQ:PLUR) stock, including its current price, historical performance, earnings information, and key financial stats. It also offers technical analysis summaries, lists ETFs holding the stock, and answers frequently asked", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/", "source_name": "TradingView", "published_at": "2026-06-11T08:39:59", "published_display": "11 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing", "summary": "Pluri's subsidiary Cellav has completed the listing of its regenerative aesthetic products with the FDA, moving closer to a commercial launch in the U.S. This development enables Cellav to market its products in the U.S. and represents a significant step for Pluri in expanding it", "url": "https://www.moomoo.com/news/post/70929169/pluri-advances-toward-us-commercial-launch-through-its-subsidiary-cellav", "source_name": "Moomoo", "published_at": "2026-06-05T20:09:40", "published_display": "05 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUR - Pluri Inc Stock Price and Quote", "summary": "This article provides detailed stock information for Pluri Inc. (PLUR), including its current stock price, financial metrics, performance indicators, and a comprehensive list of recent company news and announcements. It highlights the company's activities in biotechnology, cell t", "url": "https://finviz.com/stock?t=PLUR", "source_name": "Finviz", "published_at": "2026-06-05T05:41:00", "published_display": "05 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri subsidiary completes U.S. cosmetic listing for two products By Investing.com", "summary": "Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+. These products, designed for topical professional use, are based on plant-derived and placenta-derived form", "url": "https://ca.investing.com/news/stock-market-news/pluri-subsidiary-completes-us-cosmetic-listing-for-two-products-93CH-4671160", "source_name": "Investing.com Canada", "published_at": "2026-06-04T01:10:43", "published_display": "04 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri subsidiary completes U.S. cosmetic listing for two products", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNOS1fWU1QQnhRYi1UcnV4WmlZSnd5a0FSYlpRdHp6SVQzaVRUSm1Vb3U2ZXlPOU00d1hWMS1aRkxuS1FzS2VGbS1OVkk1ckRERzdwM3h0UFd3OWRYVjQtVzRLRE9xemt2LXpRdElCLXJzanIyRWRLelMxT3dvUkFRRFNUVEk0TkFRbGpDQ3BkRVVFd0ZQUEpoTlUyV1JOQzNweS1Edk04TmhCVlBHZWxvTVJrdHF6aDg5WmtZcA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQaF9zRXNRSEhJOXJ0RnBhY2tZQ1Rad0xlcFppd2ZxbTQzR2VMaHdudVpobEhVNC1QZHRuSEhnaVVES0dzOUtYQlU0NUNMZnFMRGMybnNEQ0xuZmpmWHM4OHRwbEVuN0tCdGJKWkEzNWd5XzRkQ3ZxeXdLQmZIQWFOVXQxWlFEbUNYUjJLX0VHNU1DcE5Gd3c?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. (PLUR) Gains 4.6%, Approaches Resistance at $2.52 - Technical Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPeGtzZ2ZzckFveFNFWEZidWwzS2dOUi04R0lKdWdxYnZKVktYOEk5em9hQ1F2ajJwNEtYOXFJTWgyU0dSV1phVHNBTXB3anN3OFZPdWU5X21jblZRa3Q2RkYtbDBWMG5qRGhnUEZJY0tXRFR2dDctQVNhN2hNLWFCNGtDdGoxOF9QMDNsUzZXNzNXVXRyVnZRaVM3RQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Insider Ups Holding During Year", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pluri-insider-ups-holding-during-105653196.html", "source_name": "Simply Wall St.", "published_at": "2026-05-28T10:56:53+00:00", "published_display": "28 May 2026 10:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pluri: Fiscal Q3 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pluri-fiscal-q3-earnings-snapshot-221201282.html", "source_name": "Associated Press", "published_at": "2026-05-14T22:12:01+00:00", "published_display": "14 May 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pluri (PLUR) Earnings Date and Reports 2026 $PLUR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9iSGRPZFFwWFlwazBQcGFING5SX2NzMWxmdUJQZW5SYUs5WTdVZV9Ta1VwN01uN3BnOHJlNjZ6NVZ5MFJBbng2OEVuRUZnWG9wLVpFdkVOOU1nTVo1QmFxMjZnLTFkZw?oc=5", "source_name": "MarketBeat", "published_at": "2022-08-02T17:03:48+00:00", "published_display": "02 Aug 2022 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for PLURI INC (PLUR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9XRXRrazltSzkzNmp6eE5tLWRXUFVrNm14UFMwSnpkczktWEswTC1nUFNaOUtoTXcyd0RRb0MzLTFLcXV3dlpIQUtRSUVwUzJibWdhaHBieDhqLTlwa2pWWWZfT1R1QzB4RE14bHcxc1hXUEJJVUhQeg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-07-27T10:25:50+00:00", "published_display": "27 Jul 2022 10:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluristem Therapeutics Inc. Changes its Name to \u201cPluri", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2022-07-25T07:00:00+00:00", "published_display": "25 Jul 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Pluri chairman raises stake above 30%; shares up", "summary": "Pluri's chairman, Zami Aberman, has increased his stake in the company to over 30%, reflecting strong confidence in the biotech firm without triggering a mandatory tender offer. This significant acquisition led to an almost 10% rise in Pluri's shares. The company is actively deve", "url": "https://www.msn.com/en-us/money/companies/pluri-chairman-raises-stake-above-30-shares-up/ar-AA27TQNh", "source_name": "MSN", "published_at": "2026-07-15T00:11:21", "published_display": "15 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Chairman Builds 30%-Plus Position With $17M Investment", "summary": "Pluri Inc. announced that Chairman Alejandro Weinstein has invested over $17 million in the company during the past year, increasing his ownership to more than 30%. This significant investment includes a $1.25 million advance made in June 2026, coinciding with Pluri's strategic s", "url": "https://www.stocktitan.net/news/PLUR/pluri-chairman-alejandro-weinstein-s-cumulative-investment-exceeds-nxv79id2x61f.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:10:33", "published_display": "14 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 88, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Chairman Alejandro Weinstein\u2019s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%", "summary": "Pluri Inc. Chairman Alejandro Weinstein has increased his investment in the company to over $17 million, resulting in an ownership stake exceeding 30%. This significant commitment comes as Pluri transitions its focus towards commercialization, particularly in the longevity sector", "url": "https://finance.yahoo.com/healthcare/articles/pluri-chairman-alejandro-weinstein-cumulative-110000776.html", "source_name": "Market source", "published_at": "2026-07-14T11:10:33", "published_display": "14 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Pluri Inc. (PLUR) received a notice from Nasdaq on July 7, 2026, indicating non-compliance with Listing Rule 5550(b)(2) due to failing to maintain a market value of listed securities of at least $35 million or meet alternative equity or net income standards. The company has 180 d", "url": "https://www.tradingview.com/news/tradingview:626ab314ea8be:0-pluri-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-07-13T20:13:27", "published_display": "13 Jul 2026 20:13", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri (PLUR) director Doron Shorrer files Form 3 listing share holdings", "summary": "Pluri Inc. director Doron Shorrer has filed a Form 3, disclosing his beneficial ownership of the company's common stock. The filing indicates direct ownership of 6,659 shares and indirect ownership of 6,969 shares through Shorrer International Ltd. This initial statement is requi", "url": "https://www.stocktitan.net/sec-filings/PLUR/form-3-pluri-inc-initial-statement-of-beneficial-ownership-085f3cdc66b9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:10:28", "published_display": "07 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUR - Pluri Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Pluri Inc. (PLUR). It includes key metrics such as market capitalization, income, sales, earnings per share, insider ownership, and various performance indicators. The data offers an overview of the", "url": "https://finviz.com/stock?t=PLUR&ty=lf&r=ytd&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T05:40:59", "published_display": "04 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Q2 2026 Earnings: Wider-than-Expected Loss Drives Stock Decline - Slow Growth Warning", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQcmVxLXN5UTRQcV8ySUpzX0dlcHdzdDB4MXk3SjdsM3g1NUZXTk5KTkFhbF95X0tSUHFqQ3Nqbm44YWtwYXhqdjNsOTdVSEZBWlJLX0EwR3NiZE10RE1MVGU5Wk4xLTZXMVhpVElOM1FGblp6YzlFRzJzYmNZaDhHR1B3X1hDNTNKTnJpVTZSZnV5VFlPQjQtUGVyV2M5X0doS09BLUp5WnBPN1o2NXNjNV9R?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T09:48:48+00:00", "published_display": "02 Jul 2026 09:48", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Pluri Inc. For: 1 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13D/A by Pluri Inc. for July 1st. It serves as a brief financial markets update, indicating a specific regulatory filing by the company. The text predominantly features navigation, advertisements, and market data rather", "url": "https://uk.investing.com/news/stock-market-news/form-13da-pluri-inc-for-1-july-93CH-4753582", "source_name": "Investing.com UK", "published_at": "2026-07-01T21:06:00", "published_display": "01 Jul 2026 21:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri (NASDAQ: PLUR) director logs RSU grant as 625,000 warrants expire", "summary": "Pluri Inc. director Alexandre Weinstein reported receiving 641 shares of common stock as an RSU grant, increasing his directly held shares to 6,925. Separately, 625,000 common warrants held indirectly through Chutzpah Holdings LP, with an exercise price of $4.25 per share, expire", "url": "https://www.stocktitan.net/sec-filings/PLUR/form-4-pluri-inc-insider-trading-activity-9d8cc2dab38b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:42", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] Pluri Inc. Amended Major Shareholder Report", "summary": "This amended Schedule 13D/A filing for Pluri Inc. details the updated beneficial ownership of major shareholder Alexandre Weinstein and his affiliated entities (Chutzpah Holdings Ltd., Chutzpah Holdings LP, and Plantae Bioscience Ltd.). As of June 30, 2026, the group beneficially", "url": "https://www.stocktitan.net/sec-filings/PLUR/schedule-13d-a-pluri-inc-amended-major-shareholder-report-f0a7bfe95f62.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:42", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pluri Inc. \u2013 NASDAQ:PLUR", "summary": "This article provides financial data for Pluri Inc. (NASDAQ: PLUR), specifically focusing on its price-to-sales forward ratio. The content appears to be a snapshot from a financial platform like TradingView, showing an overview of the company's financials without detailed analysi", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:45", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pluri Inc. \u2013 NASDAQ:PLUR", "summary": "This article provides a financial overview of Pluri Inc. (NASDAQ: PLUR), focusing on its enterprise value to EBITDA forward metric. The content is primarily a data page from TradingView, displaying key financial information for the biotechnology company. It categorizes PLUR withi", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:09:05", "published_display": "27 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pluri Inc. \u2013 NASDAQ:PLUR", "summary": "The article provides a brief overview of Pluri Inc. (NASDAQ: PLUR), focusing on its price to earnings forward metric. It appears to be an excerpt from a financial data platform, showing the company's stock market information and some underlying data sources.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:06", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Actuals & Estimates (NASDAQ:PLUR)", "summary": "This article provides financial actuals and estimates for Pluri Inc. (NASDAQ:PLUR), including its current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings date. It also covers the company's net income, employee count, EBITDA, and te", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:06", "published_display": "26 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Actuals & Estimates (FWB:4DX)", "summary": "This article provides financial actuals and estimates for Pluri Inc. (FWB:4DX), covering income statement, balance sheet, and cash flow data, as well as valuation metrics. It includes frequently asked questions about the company's stock ticker, historical prices, earnings reports", "url": "https://www.tradingview.com/symbols/FWB-4DX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:49", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. Actuals & Estimates (TASE:PLUR)", "summary": "This article provides an overview of Pluri Inc. (TASE:PLUR) stock, including its current price, historical performance, market capitalization, and financial estimates. It highlights recent stock price changes, upcoming earnings reports, and key financial metrics like net income a", "url": "https://www.tradingview.com/symbols/TASE-PLUR/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-25T20:40:50", "published_display": "25 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Pluri Inc (PLUR), indicating a current risk score of 2.15, ranking it 235 out of 387 in the Biotechnology & Medical Research industry. Key metrics include a beta value of 0.66, suggesting lower volatility compared to the S&P 500, a 240-", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-25T02:09:49", "published_display": "25 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri (NASDAQ: PLUR) gets $1,250,000 insider advance and appoints new director", "summary": "Pluri Inc. (NASDAQ: PLUR) received a $1,250,000 advance from Chutzpah Holdings LP, an entity beneficially owned by the company's chairman, to be used for working capital and general corporate purposes, with the expectation that it will be credited against securities purchased in ", "url": "https://www.stocktitan.net/sec-filings/PLUR/8-k-pluri-inc-reports-material-event-88087e271e18.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:24", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pluri Inc (PLUR), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock is currently trading between support at $1.81 and resistance at $2.42, with indicators and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/technical", "source_name": "TradingKey", "published_at": "2026-06-22T15:40:10", "published_display": "22 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Pluri Inc (PLUR), highlighting that no earnings forecast score is currently available, but the industry average is 8.15. Analysts project a price target of $12.00 for PLUR, with expected revenue of $655.00K for the next quarter. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:13", "published_display": "18 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Pluri Inc (PLUR), highlighting its current valuation score of 8.50 within the Biotechnology & Medical Research industry, ranking 124 out of 389. The company's P/E ratio is noted at -0.69, which is below its recent high and above its r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:13", "published_display": "18 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Institutional Confidence", "summary": "The article analyzes the institutional confidence score for Pluri Inc (PLUR), which currently stands at 3.00, ranking it 193 out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 14.97% quarter-over-quarter to 12.5", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:39:18", "published_display": "18 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article displays the revenue breakdown for Pluri Inc (PLUR) but notes that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It serves primarily as a placeholder or an indication that this informat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T04:39:43", "published_display": "18 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Pluri Inc (PLUR) has a weak financial status with a score of 5.30, ranking low within the Biotechnology & Medical Research industry. The company reported a significant year-over-year decrease in revenue by 60.89% to $167.00K, alongside a 9.74% decrease in net profit. Its operatio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plur/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:43", "published_display": "18 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUR Stock Price and Chart \u2014 NASDAQ:PLUR", "summary": "This article provides a detailed overview of Pluri Inc. (NASDAQ:PLUR) stock, including its current price, historical performance, earnings information, and key financial stats. It also offers technical analysis summaries, lists ETFs holding the stock, and answers frequently asked", "url": "https://www.tradingview.com/symbols/NASDAQ-PLUR/", "source_name": "TradingView", "published_at": "2026-06-11T08:39:59", "published_display": "11 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing", "summary": "Pluri's subsidiary Cellav has completed the listing of its regenerative aesthetic products with the FDA, moving closer to a commercial launch in the U.S. This development enables Cellav to market its products in the U.S. and represents a significant step for Pluri in expanding it", "url": "https://www.moomoo.com/news/post/70929169/pluri-advances-toward-us-commercial-launch-through-its-subsidiary-cellav", "source_name": "Moomoo", "published_at": "2026-06-05T20:09:40", "published_display": "05 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUR - Pluri Inc Stock Price and Quote", "summary": "This article provides detailed stock information for Pluri Inc. (PLUR), including its current stock price, financial metrics, performance indicators, and a comprehensive list of recent company news and announcements. It highlights the company's activities in biotechnology, cell t", "url": "https://finviz.com/stock?t=PLUR", "source_name": "Finviz", "published_at": "2026-06-05T05:41:00", "published_display": "05 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri subsidiary completes U.S. cosmetic listing for two products By Investing.com", "summary": "Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+. These products, designed for topical professional use, are based on plant-derived and placenta-derived form", "url": "https://ca.investing.com/news/stock-market-news/pluri-subsidiary-completes-us-cosmetic-listing-for-two-products-93CH-4671160", "source_name": "Investing.com Canada", "published_at": "2026-06-04T01:10:43", "published_display": "04 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri subsidiary completes U.S. cosmetic listing for two products", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNOS1fWU1QQnhRYi1UcnV4WmlZSnd5a0FSYlpRdHp6SVQzaVRUSm1Vb3U2ZXlPOU00d1hWMS1aRkxuS1FzS2VGbS1OVkk1ckRERzdwM3h0UFd3OWRYVjQtVzRLRE9xemt2LXpRdElCLXJzanIyRWRLelMxT3dvUkFRRFNUVEk0TkFRbGpDQ3BkRVVFd0ZQUEpoTlUyV1JOQzNweS1Edk04TmhCVlBHZWxvTVJrdHF6aDg5WmtZcA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQaF9zRXNRSEhJOXJ0RnBhY2tZQ1Rad0xlcFppd2ZxbTQzR2VMaHdudVpobEhVNC1QZHRuSEhnaVVES0dzOUtYQlU0NUNMZnFMRGMybnNEQ0xuZmpmWHM4OHRwbEVuN0tCdGJKWkEzNWd5XzRkQ3ZxeXdLQmZIQWFOVXQxWlFEbUNYUjJLX0VHNU1DcE5Gd3c?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Inc. (PLUR) Gains 4.6%, Approaches Resistance at $2.52 - Technical Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPeGtzZ2ZzckFveFNFWEZidWwzS2dOUi04R0lKdWdxYnZKVktYOEk5em9hQ1F2ajJwNEtYOXFJTWgyU0dSV1phVHNBTXB3anN3OFZPdWU5X21jblZRa3Q2RkYtbDBWMG5qRGhnUEZJY0tXRFR2dDctQVNhN2hNLWFCNGtDdGoxOF9QMDNsUzZXNzNXVXRyVnZRaVM3RQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri Insider Ups Holding During Year", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pluri-insider-ups-holding-during-105653196.html", "source_name": "Simply Wall St.", "published_at": "2026-05-28T10:56:53+00:00", "published_display": "28 May 2026 10:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri: Fiscal Q3 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pluri-fiscal-q3-earnings-snapshot-221201282.html", "source_name": "Associated Press", "published_at": "2026-05-14T22:12:01+00:00", "published_display": "14 May 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluri (PLUR) Earnings Date and Reports 2026 $PLUR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9iSGRPZFFwWFlwazBQcGFING5SX2NzMWxmdUJQZW5SYUs5WTdVZV9Ta1VwN01uN3BnOHJlNjZ6NVZ5MFJBbng2OEVuRUZnWG9wLVpFdkVOOU1nTVo1QmFxMjZnLTFkZw?oc=5", "source_name": "MarketBeat", "published_at": "2022-08-02T17:03:48+00:00", "published_display": "02 Aug 2022 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for PLURI INC (PLUR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9XRXRrazltSzkzNmp6eE5tLWRXUFVrNm14UFMwSnpkczktWEswTC1nUFNaOUtoTXcyd0RRb0MzLTFLcXV3dlpIQUtRSUVwUzJibWdhaHBieDhqLTlwa2pWWWZfT1R1QzB4RE14bHcxc1hXUEJJVUhQeg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-07-27T10:25:50+00:00", "published_display": "27 Jul 2022 10:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pluristem Therapeutics Inc. Changes its Name to \u201cPluri", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2022-07-25T07:00:00+00:00", "published_display": "25 Jul 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 45, "sentiment_summary": {"positive": 5, "negative": 9, "neutral": 31, "score": 49, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 10.66, "count": 21}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.9, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 1.72, "latest_week": "2026-07-10", "one_week_move": -18.7, "four_week_move": -24.4, "twelve_week_move": -52.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.120026, "market_dynamics_buy_signal": false, "relative_strength": -60.180076, "fair_value_gap": -63.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 47.3214, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-18.7% over one week, -24.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 9}, {"label": "Market source", "count": 8}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "Finviz", "count": 2}, {"label": "dars.gov.et", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "MSN", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 21}, {"label": "Market update", "count": 20}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-18.7% over one week, -24.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Pluri chairman raises stake above 30%; shares up"}], "updated_at": "2026-07-17T17:47:47.850892+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}